What is HemostOD?
Founded in 2020, HemostOD operates at the intersection of synthetic biology and regenerative medicine. The company is primarily focused on addressing the critical clinical need for high-quality, scalable platelet production to treat conditions such as thrombocytopenia. Beyond basic therapeutic applications, the firm is pioneering tissue-targeted cargo delivery systems, effectively positioning itself as a key player in the next generation of precision medicine. Their unique manufacturing process, which integrates academic research with industrial scalability, provides a distinct competitive advantage in the crowded life sciences landscape. By focusing on the culture of therapeutic stem cells, HemostOD is not merely developing a product but is establishing a comprehensive ecosystem for advanced hematological interventions.
How much funding has HemostOD raised?
HemostOD has raised a total of $5.4M across 1 funding round:
Seed
$5.4M
Seed (2025): $5.4M with participation from Lichtsteiner Foundation and Polytech Ventures
Key Investors in HemostOD
Lichtsteiner Foundation
A mission-driven organization focused on impact investing within the life sciences and medtech sectors, providing essential equity backing to early-stage health pioneers.
Polytech Ventures
A Swiss-based entrepreneurial investment firm specializing in scaling innovative tech and healthtech companies through both financial support and strategic advisory services.
What's next for HemostOD?
With this major enterprise-level funding, HemostOD is expected to prioritize the expansion of its manufacturing infrastructure and the advancement of its preclinical pipeline. The strategic roadmap likely includes deepening collaborations with industry partners to validate the efficacy of its engineered platelets in diverse clinical settings. As the company moves toward subsequent development phases, the focus will shift from proof-of-concept to regulatory readiness and large-scale production optimization. Investors are closely monitoring the firm's ability to translate its proprietary platform into tangible clinical outcomes, which will be essential for securing future growth capital and establishing long-term market dominance in the regenerative medicine sector.
See full HemostOD company page
